Study: Xia 2012, Journal of the American Academy of Dermatology
Topical eflornithine hydrochloride improves the effectiveness of standard laser hair removal for treating pseudofolliculitis barbae: a randomized, double-blinded, placebo-controlled trial
Citation
Xia Y, Cho S, Howard RS, Maggio KL (2012). Journal of the American Academy of Dermatology. PubMed id 22226431.
Cards that cite this study (1)
Each card gives its own wording for who was tested, how and what was found.
- Shaving and razor bumps (pseudofolliculitis barbae) Tier A thin
B 27 men with PFB in a military population (n=27)
Randomised, double-blind, paired right-neck/left-neck trial of laser hair removal plus eflornithine cream against laser plus placebo, 16 weeks.
The eflornithine side had a median hair reduction of 99.5% against 85.0% on the placebo side, with fewer inflammatory papules. Follow-up ended at 16 weeks.
As recorded in this card: Xia Y, Cho S, Howard RS, Maggio KL (2012), Journal of the American Academy of Dermatology, [primary]
Note: Participants' ethnicity is not stated in the abstract. Eflornithine and laser are clinic or prescription treatments.
This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.